Nasal Vaccines Market
完整報告名稱與涵蓋範圍
Nasal Vaccines Market Size, Share & Trends Analysis Report By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, and Conjugate Vaccines), By Application (Influenza, COVID-19), By Region, And By Segment Forecasts, 2025-2034
報告摘要
In 2024, the Nasal Vaccines Market worldwide was assessed at USD 466.2 Million. Analysts project it will surge to USD 935.2 Million by 2034, at a CAGR of 8.6% spanning 2025 to 2034.
Nasal Vaccines encompasses a non-invasive substitute for conventional injection-based medication, offering a new and efficient method of protection against a range of infectious illnesses. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Several factors contribute to this trajectory, including heightened need next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Nasal Vaccines Market Snapshot
Chapter 4. Global Nasal Vaccines Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Nasal Vaccines Market Industry Trends
4.10. Global Nasal Vaccines Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Nasal Vaccines Market Segmentation 1: By Vaccine Type, Estimates & Trend Analysis
5.1. Market Share by Vaccine Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Vaccine Type:
5.2.1. Live Attenuated Vaccines
5.2.2. Inactivated Vaccines
5.2.3. Subunit
5.2.4. Recombinant and Conjugate Vaccines
5.2.5. Others
Chapter 6. Nasal Vaccines Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Influenza
6.2.2. COVID-19
6.2.3. Others
Chapter 7. Nasal Vaccines Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. Global Nasal Vaccines Market, Regional Snapshot 2024 & 2034
7.2. North America
7.2.1. North America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.2.1.1. US
7.2.1.2. Canada
7.2.2. North America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
7.2.3. North America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.3. Europe
7.3.1. Europe Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe
7.3.2. Europe Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
7.3.3. Europe Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.4. Asia Pacific
7.4.1. Asia Pacific Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Southeast Asia
7.4.1.7. Rest of Asia Pacific
7.4.2. Asia Pacific Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
7.4.3. Asia Pacific Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.5. Latin America
7.5.1. Latin America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
7.5.3. Latin America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.6. Middle East & Africa
7.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.6.1.1. GCC Countries
7.6.1.2. South Africa
7.6.1.3. Rest of Middle East and Africa
7.6.2. Middle East & Africa Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
7.6.3. Middle East & Africa Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Vaxart, Inc.
8.2.1.1. Business Overview
8.2.1.2. Key Service/Service Overview
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. FluGen Inc.
8.2.3. Altimmune, Inc.
8.2.4. Sinovac Biotech Ltd.
8.2.5. Sanofi Pasteur SA
8.2.6. Pfizer Inc.
8.2.7. GlaxoSmithKline plc
8.2.8. Johnson & Johnson
8.2.9. Ennaid Therapeutics, LLC
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們